RxDoctor Payments Data

Christopher Paronish, MD

Family Medicine · Carrolltown, PANPI 1053332601

Payments from drug & device makers

$13,443in general payments, 2019–2025

Across 907 payments — averaging $14.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$1K
  • AstraZeneca$1K
  • Amarin Pharma, Inc.$746
  • Kowa Pharmaceuticals America, Inc.$719
  • Novartis$681
  • plus $6K from 34 others

What the payments were for

  • Food & beverage$13,422100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,443 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$47,684
Medicare patients
148
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide373$493,791
JardianceEmpagliflozin168$163,800
EliquisApixaban126$110,509
FarxigaDapagliflozin Propanediol56$55,253
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$52,727
ProliaDenosumab32$52,196
TradjentaLinagliptin80$51,482
Repatha SureclickEvolocumab96$50,355
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog69$49,798
XareltoRivaroxaban68$48,765
VascepaIcosapent Ethyl64$39,004
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog57$26,708
TrulicityDulaglutide20$23,061
MyrbetriqMirabegron24$22,861
Synjardy XrEmpagliflozin/Metformin Hcl23$22,532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,394$493,791373 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy, Jentadueto$521$266,538325 claims
PfizerEliquis$477$110,509126 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$634$77,825117 claims
AstraZenecaFarxiga$1,290$55,25356 claims
AmgenProlia$1,342$52,19632 claims
Johnson & JohnsonXarelto$273$48,76568 claims
Lilly USA, LLCTrulicity, Mounjaro$66$40,20438 claims
MerckJanumet, Januvia, Janumet Xr$283$37,53747 claims
Astellas Pharma US IncMyrbetriq$177$22,86124 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$617$17,17629 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$86$15,21120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Carrolltown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →